Xoma (XOMA) receives an Orphan Drug Designation from the FDA for gevokizumab, its IL-1 beta...

|About: XOMA Corporation (XOMA)|By:, SA News Editor

Xoma (XOMA) receives an Orphan Drug Designation from the FDA for gevokizumab, its IL-1 beta modulating antibody for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis. Shares +2.2% AH.